Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public He...
Emergent Biosolutions, Inc. (EBS)
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: Yahoo! Finance
contract modification has been executed in the amount of $56 million to supply ACAM2000 ® , (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government. Deliveries are expected to begin this month. This brings the total projected sales for ACAM2000 ® vaccine and ancillary products to more than $120 million this year from a diverse base of customers. ACAM2000 ® is licensed for active immunization against smallpox and mpox disease for persons determined to be at high risk for smallpox or mpox infection. “Our new contract modification for ACAM2000 ® vaccine reflects the continued collaboration between Emergent and the U.S. government to prioritize preparedness support,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “With our North American manufacturing and supply chain capabilities at the ready, and Emergent's commitment to being a trusted partner of the U.S. government and offering most favored pricing as
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent Biosolutions, Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Emergent Biosolutions (NYSE:EBS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada SiteGlobeNewswire
- Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EBS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
- Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
EBS
Earnings
- 10/29/25 - Beat
EBS
Analyst Actions
- 12/16/25 - HC Wainwright
EBS
Sec Filings
- 12/22/25 - Form 144
- 12/16/25 - Form 4
- 12/12/25 - Form 8-K
- EBS's page on the SEC website